investors butt a 50/50 chance on biogen winning tp it doesn't risk off the table biogen faces another decision expected by late summer or fall. analysts say the win today could increase chances there as well the drug drawing 4.4 billion in revenue. has exclusivity until 2028 bierjen investor attention turns to the alzheimer space where the company is expected to file for fda pruchl of the drug any day that of course is the reason for the massive fall and rise of the stock in the last carrier. analysts expect the roller coaster could continue as it goes through the regulatory process. >> who has a thought on biogen too hot to touch or not. >> it's not. when we talked about this in the spring the market was discounting everything biogen had everything going forward. i was shocked is traded as low it did and as long as it did but i think biogen is just getting going. this is a plus, absolutely but the alzheimer's news could be huge. you could talk about a stock i don't like to speak in hyperbowl. this stock could go up a twofer. i think we're going there. >> it's binary meg did her spot

biogen over the new stake. and berk shir bought the spy and the voop ber berkshire remember it it could be warren, todd combs, doesn't mean warren himself. berk shir raised stakes in general motors, occidental petroleum. resortation hardware and sun core energy. by my math he sold a massive 60 some million share stake in wells fargo and trimming goldman sachs, tim seymour, there is more to dig into here. what if any of the moves sticks out to you. >> the move in kroger certainly is interesting because first of all kroger had a massive move in year end depending on again you get the information it's dated in hindsight. but you knowthe question for me -- profits in supermarkets are going one way. look at this going down and ultimately you have a dynamic where you have a very overstored competitive landscape where i think we know all the big box stores are involved. i would not be a major buyer of kroger here. but i think there's been a turn around there and a margin story. and you have to give the oracle of omaha

biog biogen on february 14th we were doing it right there in englewood cliffs we talked about the 292 dashes 295 calls in february they are buying in biogen last week the thing had a monster run to the upside. the calls went from 15 dollars to as high as 78 that was a nice one. we will take the loser on one side and the gaep on this side that's one that i got out of, that spike you don't know how long it will hold it was a bra run or great news for biogen and everybody else involved on that move that was exciting i am out, no longer in biogen. >> pete thanks have a good weekend. see you on the other side. >> take care. >>> straight ahead, another busy week of earnings coming up 60 s&p 500 companies one dow component set to report. names like cisco, nvidia and alibaba on that list we will take positions ahead of that. >>> first let's look at the s&p sectors. the s&p is down we will call it nine you have five sectors up, and e st down. consumer staples and utilities are leading the way. back after this. this piece is talking to me. yeah? so what do you see? i see an unbelievable opportu

a spike in kroger in particular. >> a laggard, underloved biogen as well. doing nothing in a a number of years. it plays to type in terms of if it is mr. buffett as opposed to his portfolio managers he is playing with a lot of house money in the apple stake sprinkling it around. >> or you noted that he did not sell off more. >> it would have been big news if he backed off the apple stake which he has not apparently. >> all right have a happy valentine's day a three-day holiday weekend as well that does it for "closing bell." >> "fast money" begins right now. >>> yes it does, happy friday. live from the nasdaq market site over looking times square. this is "fast money. i'm brian in for melissa lee traders are tim seymour. jeff mills welcome brian kelly and steve grasso tonight on fast. shares of canopy growth sparking a rally in the pot stocks. why bad news is not so bad news in this sector we'll dig in plus for your chart of the week we look at a name we all kind of left for dead not long ago well maybe not everyone around the table. ishe

. >>> we have a market flash on biogen meg? >> the stock is up sharply after the company won a patent decision the patent decision was against a company of mylan the stock up 19% for biogen. kelly, back to you. >> thank you >>> casper's i 3o valuation could give investors night mares. a look at whether you should get in bed with the stock when it at nt.orw.ding tomro th'sex >>> welcome back mattress start-up casper disclosing to cut the ipo price range. when casper first filed the s-1 crock documents the range 17 to $19 and now down to a range of $12 to $13 and the valuation which hit a peak of $1.1 million last year in march is just about half of that the most it's worth is $520 million and lost the unicorn status part of the problem is the pioneer of the sleep economy is doing not so disruptive things anymore. according to "the new york post," a potential investor in the thursday presentation said he decided to pass after hearing the ceo talk about the planned expansion to brick and mortar shops. the horror let's bring in bus

shares of biogen soaring >> they won a major patent decision for the multiple sclerosis drug this was a highly anticipated decision as the drug is the biggest bringing in $4.4 billion in 2019 revenue. it doesn't take all patent challenges off the table but analysts say this decision likely raises the chances biogen will win there, too. investor attention is shifting to the news on the alzheimer's front where they're expected to file any day for fda approval of their drug and that would be a big one to watch back over to you. >> thank you >>> mike, want to get your thoughts given the fact that we have seen a bounce in some of the biotech names. >> the group has gotten a bit of a tail wind. what i love is the two-year chart, this is the fourth vertical move up or down on one of these a nounments or something like that and it's gone exactly nowhere it was at 333 two years ago, it's at $333 right now and it just sort of shows you that it didn't give you a chance to figure out what was going on. so this one is kind of a quick silver thing to grab. >> more broadly, health care, mike, is get

also, the xbi very different than the ibb, excuse me, ib be, very heavy at the top with gilead and biogen et cetera. this is a very diversified play, and it's outperformed that one i think you ride those balance sheets in bio tech land. >> it's had a huge move, banging up against levels we haven't seen in many years amgen has actually pulled back you have an opportunity there as well, and even gilead is showing signs of life for the first time in a long time i'm with chris on this one. >> what's interesting, when this chart started to break out a couple months ago, it did it on huge volume. then as it consolidated earlier in the year on very low volume i think the stock's being accumulated. i think people are buying it i think there's real money behind it. typically when names are being accumulated on big volume, it means big things are ahead. >> interesting sector to continue to watch, with everything going on politically as well. >>> here we go, it's time for the final trade, this show flew by so fast >> courtney, thank you for being here mcdonald's, thank you for being there for me all

biogen, a pop to in premarket. bill: biogen surged intraday on patent news, up 2.7% in premarket trading, offered around 342 or so. it has been in these trading ranges amidst this range dating back to 2015. potential resistance today dating back to the 2015 cap. 324 and then three to 56. -- 356. alix: let's talk about twitter. bill: up around 8% in the premarket. your 200 day is 3655. that will be resistant. isve that, the october gap 3776. alix: thank you very much. that doesn't for me on "bloomberg daybreak: americas." this is bloomberg. ♪ jonathan: from new york city for our audience worldwide. i'm jonathan ferro. "the countdown to the open" starts right now. ♪ jonathan: coming up, stocks at record highs. investors gripped by fear. try to moving to -- china moving to half tariffs on u.s. imports. data in germany showing the worst is not over yet. here is your thursday morning price action. equity futures up 10. on the s&p we advance .33%. treasuries lower. yields higher, up one basis point to 1.60 6% on the

warren buffett and berkshire hathaway prayed they've been pouring money -- adding money to kroger and biogen. >> occidental is a really interesting buy. when he added to his stake in november, the stock did get a little boost over there so we will watch that into next week. we don't know how he feels yet really right now about kraft heinz. you mentioned occidental. icon is kind of reducing it's taken occidental. two heavyweights there. >> absolutely. going to net care. icon is asking for more information on occidental and potential takeover activity here. hardware, ioration don't know if you've ever been to that store. is buffett going harder into luxury retail? he is thinking about that consumer. berkshire hathaway selling goldman sachs. which is interesting given the kind of news we've heard. a brain drain. some departures of key executives. berkshire cutting its holdings after four quarters of no change when it comes to that position. >> there that long history of goldman sachs. >> we also want to mention we will have coverage on some key voices from washington. wall street week, zedd 6:0

the stocks that have really led the way for the nasdaq have been the likes of biogen and tesla, which are each up about 20% in the past five days. the gains today come despite the fact that a lot of the chip stocks arles actually lower. today on a lower mixed sales forecast for the next quarter. that has to do with 5g maybe not paying off as soon as was expected. for the semi stocks, we also have concerns about the coronavirus adding to the drag and o.n.kes of amd semiconductor. you have twitter revenue and user growth beating in the fourth quarter, adding 21% growth. cardinal it again nice beat, raising its guidance by about $.30 -- by about 30%. zynga also getting a nice earnings boost. vonnie: remember, gtv allows you to browse all of the charts featured on bloomberg. this is bloomberg. ♪ ♪ from london, i'm guy johnson. vonnie: from new york, i'm vonnie quinn. this is the european close on "bloomberg markets." we are speaking with david page of axa. want to come back to the boeing news we had a few moments ago about a new software flaw being found. this coming out from the

by the way so is biogen, got great news on a ms drug. big names that used to carry the market. they fell off a long time. could names like that get your attention. >> not ibm for me. i got email from somebody. do you think ibm is the next tesla? not. there is no growth there. the name i'm watching is boeing. if they get the act together i think it is up 150 points. i got out of tech. i will sit patient. i'm not a big believer in the value area, industrial area. i'm a growth guy. i think i get growth to pull back. then i will jump all them to buy again. charles: tesla down 23%. catch gary on "bulls & bears" 5:00 p.m. eastern time. >>> market looking at president's trump's address there was areas of agreement from both sides of the aisle as well. >> everybody said that criminal justice reform couldn't be done. but i got it done and the people in this room got it done. [cheers and applause] we must also rebuild america's infrastructure. [cheers and applause] the united states will join the 1 trillion trees initiative. i call on congress to pass the bipartisan advancing support for

look at the board and as you see the s&p a lot of big names, biogenic seen a lot of businesses week. an analyst have been raising the price targets as well pray national oil, that is very interesting because we are seeing improvements in offshore markets and international went in the makeup maker and citigroup rate let's take a look at nasdaq, i think it includes a stock of the year. take a look at tesla, their record height was $960 down $200 you cannot be 100% gains. >> absolutely. that has just been on a tear, everybody says it's a fear of missing out but we had the same thing a year ago with tesla. almost like the bull run. good to see you. happy friday. the chips are down on wall street on the final three minutes of trade. the countdown closer says it's a different kind of chip you should be betting when navigating the market. he has $25 billion under management. we welcome chief market strategist dan marshall. >> the semi conductors in general. >> microchips, we use them as a barometer and a roadmap for the market. in my opinion based on some of the research i have done there t

these are sort of marquee brand names to the american investor oracle and biogen and morgan stanley and starbucks and wells and delta and chevron. >> should be adding more health care names to that also list they haven't come down much. there is a reason. >> merck >> there is a reason >> i am trying to give you an idea the kinds of brand names that are in the majority of portfolios of the investor who watches or just plain invests. >> also, if you look at these companies, and of a modicum of confidence on the e. the p is variable because the prices are going down. whether it is like a hotel, cruise lines, what have you, you have to question the p and e because you don't know if or when it is going the snap back with health care, you look at what is happening with the gileads of the world, united health care, these are companies that are going to be around ten or 20, 30 years that are doing innovative thing, that's where the opportunity comes in to look at these, have good sense of how solid is the e nibble on those names. that's where growth is going to come in the next five, ten, 20 ye

pharmaceuticals,regeneron was one,biogen also seeing a pop more than 13% in february, and t-mobile on the positive merger news, so that all makes sense but unfortunately, liz i can't avoid those laggards so let's stick with the s&p for the monthly laggards there. more in life lock was down pretty big, more than 30% pretty big decline there, royal caribbean and norwegian cruise lines no surprise the cruises have been absolutely decimated as a result of the coronavirus. i'm going to go back to the dow because you've got big laggards related there too. exxon-mobile is one of them, oil prices have been decimated concerns about the virus, global demand, taking those prices down into the 4 handle and exxon see ing almost 20% in losses in february and then of course goldman sachs and american express because the financials have been hit hard by this too. it's really difficult, liz, to find any group or particular stocks besides maybe some of the mass makers and those potential vaccine makers that have done well this month. back to you. liz: jackie, thank you wow look at amex down 17% some of

communication services, having an up day >> 14 stocks in the s&p 500 closed up 10% or more this week, led by biogen, cody, and even twiters. >>> stacey cunningham, should you ever buy the stock of a losing company and what happened to casper? she is your closer today joining us to talk more about it, is michael zinn. dan nathan principal at risk reversal advisers. yes, today not a good day, to sara's point, but the best weeks since june for the dow why this sudden strength >> to me sudden strength is more about the market wanted a dip, said it was over-eager i think the big explanation is what has been continuing to work, which is thenasdaq 100 type stocks. the big consistent giants that have basically seen as leadership for a long time they're both quality and they're defense. they're perceived as being these battle ships, so i think it's understandable a lot of this open-ended, we don't know -- >> dan, if you do back, and we've done it before, but if you track the fed's balance sheet with the equity markets. that's the wind at our sails here, nothing has changed. >> well, it's funny, the fed chai

warren buffett of berkshire ithaway, no exception, and took a relatively small position in biogen, and even bigger state in the supermarket kroger, about 2% of its market cap at the time. news of those caused both shares to rally, kroger gaining nearly 6% after the market closed on friday. finally, what everyone wants to know about, the tech darlings. certainly a mixed quarter when it comes to alibaba. we saw funds like d1 tiger global, lone pine, all smashed their total ad for the quarter. tesla gruesome interest. this is before the first quarter rally. you had viking global attic position. one of the more popular bets was uber. we saw two big buyers that added positions. hedge funds added roughly the equivalent of 6% of its market cap. in fact, more market at $2.9 billion, was piled into uber then to facebook, tesla, and apple. matt: dani burger with a look at your winners and losers. let's get back to the earnings story with bill. bill, what do you think about the state of, let's say, european companies right now in terms of earnings season, as we get towards wrapping it up? bill: w

memory declines in the study leading some to further question the hypothesis, an approach taken by biogen chug expected to be filed for fda approval this year the stocks had been down earlier today, but they have all come back, sara. >> meg, thank you. >>> we are at session highs here, getting a nice boost into the close, mike. what are you seeing in terms of the internals? >> a little more ambiguous, still okay, but if you look at up versus down, than in up stocks you had it's the same story. >> happen the s&p 500 is not participating. it's down year to day. >> when they're plus or minus a couple >> you'll see exactly what you're talking about one is you have 9%, the other is down 10% >> you might just ask for stuff. >> i think it prepares really, really well. >> it's an exaggerated version of growth versus value, is essential what we're saying. mgk, i didn't ask for this before, but the mega path growth index, it's low yield, pushing into longer -- >>> let's get to rick santelli for a check on the bond market, which happens to be telling a very different story than the bond market, rick

. >> biogen the lows in october and then reported that look again at the data where they did see some efficacy. >> yes >> for their alzheimer's therapy. and then they came back that stock rebounded dramatically >> yes, it has this should not be lilly being in the dog house because mr. ricks who say remarkable ceo has never given this lip service, said look out. j&j explained to me that this is really the most difficult one. >> alzheimer's you mean? >> yes alzheimer's. i know we're all kind of really perplexed and scared of corona alzheimer's affects a huge number >> the cost for the health care system are immense, and there's no cure. we are making real progress, we, the industry is making real progress on cancer we talk about that all the time. >> that's where the big spend is >> alzheimer's would be by far the largest drug in the world if somebody found something that not just stopped the progression but cured it >> moderna is a stock trades up constantly i spent a lot of time with moderna when i was at the jpmorgan conference. they are the ones. fauci is saying they could have some

it took a relatively small position in biogen, but a bigger stake in kroger supermarket. 2% of its market cap. we can see it made the shares gain. kroger gained nearly 6%. the tech darlings. when it comes to alibaba, here is the total aggregated amount added. they boosted their stake, but tiger global/there's. some also drew interest. interesting and popular bets of the quarter was uber, really one of the only stocks to be at the top. the hedge funds added the equivalent of 6% of its market cap. more cash was piled into a uber than facebook, tesla or apple. francine: thank you so much. when you look at some of the earnings outlook and this goes back to the filings, but just in general, are you worried about some of the valuations we are seeing out there? maria: in one word, no. francine: into words? maria: liquidation has definitely gone up. tech is one of very few areas in the market where fundamentals are actually decent. it is very hard to find and other sector where fundamentals are quite good. the trade-off investors have to make, do they want fundamentals or cheaper price? that grow